Blue Trust Inc. Acquires 1,112 Shares of Moderna, Inc. $MRNA

Blue Trust Inc. grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 66.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,792 shares of the company’s stock after acquiring an additional 1,112 shares during the quarter. Blue Trust Inc.’s holdings in Moderna were worth $77,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of MRNA. S Bank Fund Management Ltd purchased a new stake in Moderna during the 1st quarter valued at about $25,000. TD Private Client Wealth LLC boosted its holdings in Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after acquiring an additional 743 shares during the period. SVB Wealth LLC purchased a new stake in Moderna during the 1st quarter valued at about $28,000. CX Institutional lifted its holdings in Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after buying an additional 949 shares during the period. Finally, Costello Asset Management INC purchased a new stake in Moderna in the 1st quarter worth approximately $30,000. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Morgan Stanley increased their price objective on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. Cowen initiated coverage on Moderna in a report on Sunday, July 13th. They issued a “hold” rating for the company. Citigroup initiated coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price objective for the company. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Finally, Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $39.93.

Moderna Stock Down 4.2%

MRNA stock opened at $26.01 on Friday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $57.69. The firm has a market cap of $10.16 billion, a PE ratio of -3.45 and a beta of 2.01. The business has a 50 day moving average of $25.91 and a 200 day moving average of $27.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same quarter last year, the company earned ($3.33) EPS. The firm’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.